Use of the Spatial Scan Statistic to Identify Geographic Variations in Late Stage Colorectal Cancer in California (United States)

Pollack, Lori A.; Gotway, Carol A.; Bates, Janet H.; Parikh‐Patel, Arti; Richards, Thomas B.; Seeff, Laura C.; Hodges, Holly R.; Kassim, Sidibé

doi:10.1007/s10552-005-0505-1

Cited by 37 publications

(27 citation statements)

References 34 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 1 million new cases of colorectal cancer are clinically diagnosed each year and more than 500,000 patients die from colorectal cancer annually (16). More than 20% of colorectal cancer cases are diagnosed at a late stage and this percentage is higher in developing countries (17). Thus, many patients experience recurrence after colorectal resection.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer

Zeng

Luo

Yang

et al. 2014

Clinical Cancer Research

126

110

View full text Add to dashboard Cite

Purpose: The circadian clock gene Bmal1 is involved in cancer cell proliferation and DNA damage sensitivity. The aim of this study was to explore the effect of Bmal1 on oxaliplatin sensitivity and to determine its clinical significance in colorectal cancer.Experimental Design: Three colorectal cancer cell lines, HCT116, THC8307 and HT29, were used. The Bmal1-mediated control of colorectal cancer cell proliferation was tested in vitro and in vivo. MTT and colony formation assays were performed to determine the sensitivity of colorectal cancer cells to oxaliplatin. Flow cytometry was used to examine changes in the cell-cycle distribution and apoptosis rate. Proteins expressed downstream of Bmal1 upon its overexpression were determined by Western blotting. Immunohistochemistry was used to analyze Bmal1 expression in 82 archived colorectal cancer tumors from patients treated with oxaliplatin-based regimens.Results: Bmal1 overexpression inhibited colorectal cancer cell proliferation and increased colorectal cancer sensitivity to oxaliplatin in three colorectal cancer cell lines and HCT116 cells model in vivo. Furthermore, the overall survival of patients with colorectal cancer with high Bmal1 levels in their primary tumors was significantly longer than that of patients with low Bmal1 levels (27 vs. 19 months; P ¼ 0.043). The progression-free survival of patients with high Bmal1 expression was also significantly longer than that of patients with low Bmal1 expression (11 vs. 5 months; P ¼ 0.015). Mechanistically, the effect of Bmal1 was associated with its ability to regulate G2-M arrest by activating the ATM pathway.Conclusion: Bmal1 shows the potential as a novel prognostic biomarker and may represent a new therapeutic target in colorectal cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer

Zeng

Luo

Yang

et al. 2014

Clinical Cancer Research

126

110

View full text Add to dashboard Cite

show abstract

“…Another study (Pollack et al, 2006) in California showed 57% of overall cases of colorectal cancer were diagnosed at a late stage. Californians diagnosed with latestage colorectal cancer were more likely to be Hispanic and living in areas of lower socioeconomic status.…”

Section: Introductionmentioning

confidence: 99%

Spatial Analysis of Colorectal Cancer Cases in Kuala Lumpur

Shah¹,

Neoh²,

Rahim³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Previous studies using data from a single state or province have reported associations of a variety of patient characteristics with colorectal cancer stage at diagnosis, including age, sex, race/ethnicity, comorbid conditions, insurance status, socioeconomic status, smoking status, and distance to primary care provider [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]. Halpern et al [30] used data from the National Cancer Data Base (NCDB) to evaluate the association between insurance status, race/ethnicity, and stage at diagnosis for 12 sites of cancer, including colorectal cancer, for a large patient population across the US.…”

Section: Introductionmentioning

confidence: 99%

Factors Associated with Colon Cancer Stage at Diagnosis

Halpern

Pavluck

Ko³

et al. 2009

Dig Dis Sci

View full text Add to dashboard Cite

We analyzed data from 1998-2004 from the National Cancer Data Base to evaluate associations between patient/treatment facility factors and stage at diagnosis for all colon cancers combined and by anatomic location. Compared to patients with private insurance, uninsured patients were significantly more likely to present with advanced-stage disease; Medicaid patients had likelihoods of advanced-stage colon cancer in-between those of privately insured and uninsured patients. Increased odds of advanced-stage colon cancer at diagnosis were also observed among Black (vs. White) patients, women (vs. men), and patients from low socioeconomic status (SES) regions (vs. those from higher SES regions). While the likelihood of advanced-stage disease at diagnosis decreased in later years overall, this decrease was not observed among patients with ascending colon cancers. Screening disparities may lead to more advanced stage at diagnosis among colon cancer patients; programs to improve access to screening among underserved populations may address this disparity.

show abstract

Use of the Spatial Scan Statistic to Identify Geographic Variations in Late Stage Colorectal Cancer in California (United States)

Cited by 37 publications

References 34 publications

Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer

Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer

Spatial Analysis of Colorectal Cancer Cases in Kuala Lumpur

Factors Associated with Colon Cancer Stage at Diagnosis

Contact Info

Product

Resources

About